Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie's Disease: A retrospective cohort study. [PDF]
Durukan E +5 more
europepmc +1 more source
Editorial Comment to Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve‐sparing radical prostatectomy [PDF]
Mauro Gacci
openalex +1 more source
Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders. [PDF]
Musa ZS +5 more
europepmc +1 more source
Bioactivities of a series of phosphodiesterase type 5 (PDE-5) inhibitors as modelled by MIA-QSAR
João Eustáquio Antunes +2 more
openalex +1 more source
Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta‐analysis
Huilin Tang +5 more
semanticscholar +1 more source
Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis. [PDF]
Ma C, Zhang J, Cai Z, Xiong J, Li H.
europepmc +1 more source
Demonstration of a Heat-Stable Cyclic GMP Phosphodiesterase in the Medium of Physarum flavicomum [PDF]
Lynch, Thomas J., Ross, Mark S.
core +2 more sources
Tiên T K Do, G. Theocharis, E. Reich
semanticscholar +1 more source

